dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Planas-Cerezales, Lurdes |
dc.contributor.author | Arias-Salgado, Elena G. |
dc.contributor.author | Berastegui Garcia, Cristina |
dc.contributor.author | Montes-Worboys, Ana |
dc.contributor.author | González-Montelongo, Rafaela |
dc.contributor.author | Lorenzo-Salazar, José. M. |
dc.contributor.author | Román Broto, Antonio |
dc.date.accessioned | 2022-04-22T13:10:55Z |
dc.date.available | 2022-04-22T13:10:55Z |
dc.date.issued | 2021-07 |
dc.identifier.citation | Planas-Cerezales L, Arias-Salgado EG, Berastegui C, Montes-Worboys A, González-Montelongo R, Lorenzo-Salazar JM, et al. Lung Transplant Improves Survival and Quality of Life Regardless of Telomere Dysfunction. Front Med. 2021 Jul;8:695919. |
dc.identifier.issn | 2296-858X |
dc.identifier.uri | https://hdl.handle.net/11351/7375 |
dc.description | Lung transplantation; Pulmonary fibrosis; Telomere disorders |
dc.description.abstract | Introduction: Fibrotic interstitial lung diseases (ILDs) are the first indication for lung transplantation (LT). Telomere dysfunction has been associated with poor post-transplant outcomes. The aim of the study was to evaluate the morbi-mortality and quality of life in fibrotic ILDs after lung transplant depending on telomere biology.
Methods: Fibrotic ILD patients that underwent lung transplant were allocated to two arms; with or without telomere dysfunction at diagnosis based on the telomere length and telomerase related gene mutations revealed by whole-exome sequencing. Post-transplant evaluation included: (1) short and long-term mortality and complications and (2) quality of life.
Results: Fifty-five percent of patients that underwent LT carried rare coding mutations in telomerase-related genes. Patients with telomere shortening more frequently needed extracorporeal circulation and presented a higher rate of early post-transplant hematological complications, longer stay in the intensive care unit (ICU), and a higher number of long-term hospital admissions. However, post-transplant 1-year survival was higher than 80% regardless of telomere dysfunction, with improvement in the quality of life and oxygen therapy withdrawal.
Conclusions: Post-transplant morbidity is higher in patients with telomere dysfunction and differs according to elapsed time from transplantation. However, lung transplant improves survival and quality of life and the associated complications are manageable. |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Medicine;8 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Pulmons - Trasplantació |
dc.subject | Fibrosi pulmonar - Aspectes genètics |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Lung Transplantation |
dc.subject.mesh | Lung Diseases, Interstitial |
dc.subject.mesh | /genetics |
dc.subject.mesh | Treatment Outcome |
dc.title | Lung Transplant Improves Survival and Quality of Life Regardless of Telomere Dysfunction |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fmed.2021.695919 |
dc.subject.decs | trasplante de pulmón |
dc.subject.decs | enfermedades pulmonares intersticiales |
dc.subject.decs | /genética |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.3389/fmed.2021.695919 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Planas-Cerezales L, Montes-Worboys A] ILD Multidisciplinary Unit, Hospital Universitari Bellvitge, IDIBELL, Universitat de Barcelona, Hospitalet de Llobregat, Spain. [Arias-Salgado EG] Biomedical Research Institute CSIC/UAM, IdIPAZ, Madrid, Spain. Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain. [Berastegui C, Román A] Servei de Pneumologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [González-Montelongo R, Lorenzo-Salazar JM] Genomics Division, Instituto Tecnológico y de Energías Renovables, Santa Cruz de Tenerife, Spain |
dc.identifier.pmid | 34395476 |
dc.identifier.wos | 000691305800001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |